Nektar Therapeutics
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders in the United States and internationally. It develops NKTR-358, a regulatory T (Treg) cell stimulator designed to address the imbalance in the immune system underlying autoimmune disorders and chronic inflammatory conditions; P… Read more
Nektar Therapeutics (NKTR) - Net Assets
Latest net assets as of September 2025: $85.09 Million USD
Based on the latest financial reports, Nektar Therapeutics (NKTR) has net assets worth $85.09 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($301.35 Million) and total liabilities ($216.26 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $85.09 Million |
| % of Total Assets | 28.24% |
| Annual Growth Rate | 4.68% |
| 5-Year Change | -94.36% |
| 10-Year Change | 844.73% |
| Growth Volatility | 414.66 |
Nektar Therapeutics - Net Assets Trend (1994–2024)
This chart illustrates how Nektar Therapeutics's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Nektar Therapeutics (1994–2024)
The table below shows the annual net assets of Nektar Therapeutics from 1994 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $60.74 Million | -53.63% |
| 2023-12-31 | $130.99 Million | -64.27% |
| 2022-12-31 | $366.64 Million | -46.04% |
| 2021-12-31 | $679.51 Million | -36.92% |
| 2020-12-31 | $1.08 Billion | -23.35% |
| 2019-12-31 | $1.41 Billion | -18.18% |
| 2018-12-31 | $1.72 Billion | +1855.61% |
| 2017-12-31 | $87.83 Million | -0.34% |
| 2016-12-31 | $88.12 Million | +1270.74% |
| 2015-12-31 | $6.43 Million | -82.30% |
| 2014-12-31 | $36.33 Million | +140.41% |
| 2013-12-31 | $-89.90 Million | -291.21% |
| 2012-12-31 | $47.02 Million | -76.23% |
| 2011-12-31 | $197.81 Million | +118.19% |
| 2010-12-31 | $90.66 Million | -11.43% |
| 2009-12-31 | $102.37 Million | -46.17% |
| 2008-12-31 | $190.15 Million | -11.32% |
| 2007-12-31 | $214.44 Million | -5.56% |
| 2006-12-31 | $227.06 Million | -30.52% |
| 2005-12-31 | $326.81 Million | -30.07% |
| 2004-12-31 | $467.34 Million | +184.63% |
| 2003-12-31 | $164.19 Million | -20.59% |
| 2002-12-31 | $206.77 Million | -23.51% |
| 2001-12-31 | $270.31 Million | -2.72% |
| 2000-12-31 | $277.88 Million | +220.77% |
| 1999-12-31 | $86.63 Million | -25.24% |
| 1998-12-31 | $115.88 Million | +19.35% |
| 1997-12-31 | $97.09 Million | +176.62% |
| 1996-12-31 | $35.10 Million | +73.76% |
| 1995-12-31 | $20.20 Million | +31.17% |
| 1994-12-31 | $15.40 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Nektar Therapeutics's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 358611000000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $19.00K | 0.03% |
| Other Comprehensive Income | $61.00K | 0.10% |
| Other Components | $3.66 Billion | 6020.82% |
| Total Equity | $60.74 Million | 100.00% |
Nektar Therapeutics Competitors by Market Cap
The table below lists competitors of Nektar Therapeutics ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Fujian Huoju Electronic
SHG:603678
|
$1.42 Billion |
|
American Superconductor Corporation
NASDAQ:AMSC
|
$1.42 Billion |
|
LIVZON PHARMAC. GRP H YC1
F:LP6
|
$1.42 Billion |
|
The Ramco Cements Limited
NSE:RAMCOCEM
|
$1.42 Billion |
|
Vericel Corporation
F:ATQP
|
$1.42 Billion |
|
Jiangsu Dingsheng New Material Joint-Stock Co Ltd
SHG:603876
|
$1.42 Billion |
|
JUSUNG ENGINEERING Co. Ltd
KQ:036930
|
$1.42 Billion |
|
SIGMAROC PLC LS -01
F:M2I2
|
$1.42 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Nektar Therapeutics's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 130,987,000 to 60,737,000, a change of -70,250,000 (-53.6%).
- Net loss of 118,961,000 reduced equity.
- Share repurchases of 3,000,000 reduced equity.
- Other comprehensive income decreased equity by 19,000.
- Other factors increased equity by 51,730,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-118.96 Million | -195.86% |
| Share Repurchases | $3.00 Million | -4.94% |
| Other Comprehensive Income | $-19.00K | -0.03% |
| Other Changes | $51.73 Million | +85.17% |
| Total Change | $- | -53.63% |
Book Value vs Market Value Analysis
This analysis compares Nektar Therapeutics's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 16.94x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 4.00x to 16.94x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1994-12-31 | $18.74 | $75.06 | x |
| 1995-12-31 | $15.35 | $75.06 | x |
| 1996-12-31 | $23.17 | $75.06 | x |
| 1997-12-31 | $52.80 | $75.06 | x |
| 1998-12-31 | $55.29 | $75.06 | x |
| 1999-12-31 | $38.20 | $75.06 | x |
| 2000-12-31 | $99.25 | $75.06 | x |
| 2001-12-31 | $76.31 | $75.06 | x |
| 2002-12-31 | $56.10 | $75.06 | x |
| 2003-12-31 | $44.12 | $75.06 | x |
| 2004-12-31 | $89.35 | $75.06 | x |
| 2005-12-31 | $57.06 | $75.06 | x |
| 2006-12-31 | $37.93 | $75.06 | x |
| 2007-12-31 | $35.01 | $75.06 | x |
| 2008-12-31 | $30.87 | $75.06 | x |
| 2009-12-31 | $16.55 | $75.06 | x |
| 2010-12-31 | $14.46 | $75.06 | x |
| 2011-12-31 | $26.27 | $75.06 | x |
| 2012-12-31 | $0.41 | $75.06 | x |
| 2013-12-31 | $-0.78 | $75.06 | x |
| 2014-12-31 | $4.30 | $75.06 | x |
| 2015-12-31 | $0.73 | $75.06 | x |
| 2016-12-31 | $9.47 | $75.06 | x |
| 2017-12-31 | $0.56 | $75.06 | x |
| 2018-12-31 | $9.54 | $75.06 | x |
| 2019-12-31 | $120.47 | $75.06 | x |
| 2020-12-31 | $90.49 | $75.06 | x |
| 2021-12-31 | $55.61 | $75.06 | x |
| 2022-12-31 | $29.39 | $75.06 | x |
| 2023-12-31 | $10.34 | $75.06 | x |
| 2024-12-31 | $4.43 | $75.06 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Nektar Therapeutics utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -195.86%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -120.86%
- • Asset Turnover: 0.32x
- • Equity Multiplier: 5.00x
- Recent ROE (-195.86%) is below the historical average (-111.20%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1994 | -34.42% | -311.76% | 0.10x | 1.12x | $-6.84 Million |
| 1995 | -38.12% | -226.47% | 0.15x | 1.15x | $-9.72 Million |
| 1996 | -28.49% | -144.93% | 0.17x | 1.18x | $-13.51 Million |
| 1997 | -10.28% | -61.44% | 0.14x | 1.23x | $-19.69 Million |
| 1998 | -15.84% | -84.22% | 0.16x | 1.16x | $-29.94 Million |
| 1999 | -44.38% | -92.96% | 0.18x | 2.62x | $-47.11 Million |
| 2000 | -35.05% | -188.66% | 0.08x | 2.27x | $-125.19 Million |
| 2001 | -92.49% | -322.72% | 0.12x | 2.47x | $-277.04 Million |
| 2002 | -51.97% | -113.31% | 0.16x | 2.93x | $-128.15 Million |
| 2003 | -28.43% | -43.93% | 0.17x | 3.76x | $-63.10 Million |
| 2004 | -21.80% | -89.16% | 0.15x | 1.59x | $-148.62 Million |
| 2005 | -56.64% | -146.59% | 0.15x | 2.63x | $-217.79 Million |
| 2006 | -68.16% | -71.08% | 0.28x | 3.38x | $-177.47 Million |
| 2007 | -15.28% | -12.00% | 0.38x | 3.38x | $-54.20 Million |
| 2008 | -18.06% | -38.07% | 0.16x | 2.95x | $-53.35 Million |
| 2009 | -100.15% | -142.52% | 0.12x | 5.62x | $-112.76 Million |
| 2010 | -41.85% | -23.85% | 0.31x | 5.75x | $-47.00 Million |
| 2011 | -67.73% | -187.43% | 0.12x | 3.07x | $-153.76 Million |
| 2012 | -365.51% | -211.67% | 0.16x | 10.59x | $-176.56 Million |
| 2013 | 0.00% | -108.79% | 0.34x | 0.00x | $-153.02 Million |
| 2014 | -148.40% | -26.86% | 0.45x | 12.16x | $-57.55 Million |
| 2015 | -1262.67% | -35.17% | 0.46x | 78.09x | $-81.82 Million |
| 2016 | -174.21% | -92.80% | 0.29x | 6.46x | $-162.34 Million |
| 2017 | -110.09% | -31.42% | 0.60x | 5.79x | $-105.47 Million |
| 2018 | 39.67% | 57.09% | 0.55x | 1.25x | $509.56 Million |
| 2019 | -31.36% | -384.47% | 0.06x | 1.41x | $-581.21 Million |
| 2020 | -41.26% | -290.65% | 0.10x | 1.43x | $-552.17 Million |
| 2021 | -77.09% | -514.03% | 0.09x | 1.64x | $-591.79 Million |
| 2022 | -100.43% | -399.98% | 0.13x | 1.94x | $-404.86 Million |
| 2023 | -210.75% | -306.31% | 0.23x | 3.04x | $-289.15 Million |
| 2024 | -195.86% | -120.86% | 0.32x | 5.00x | $-125.03 Million |
Industry Comparison
This section compares Nektar Therapeutics's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Nektar Therapeutics (NKTR) | $85.09 Million | -34.42% | 2.54x | $1.42 Billion |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |